THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Ira Targoff to Myositis

This is a "connection" page, showing publications Ira Targoff has written about Myositis.
Connection Strength

5.781
  1. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008 Aug; 10(4):333-40.
    View in: PubMed
    Score: 0.299
  2. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006 Jun; 8(3):196-203.
    View in: PubMed
    Score: 0.258
  3. Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology (Oxford). 2023 02 23; 62(SI2):SI226-SI234.
    View in: PubMed
    Score: 0.205
  4. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002 Nov; 28(4):859-90, viii.
    View in: PubMed
    Score: 0.201
  5. Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies. Ann Rheum Dis. 2023 Feb; 82(2):235-245.
    View in: PubMed
    Score: 0.200
  6. Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis. Rheumatology (Oxford). 2022 07 06; 61(7):2969-2977.
    View in: PubMed
    Score: 0.196
  7. Environmental factors associated with juvenile idiopathic inflammatory myopathy clinical and serologic phenotypes. Pediatr Rheumatol Online J. 2022 Apr 12; 20(1):28.
    View in: PubMed
    Score: 0.193
  8. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000 Nov; 12(6):475-81.
    View in: PubMed
    Score: 0.175
  9. Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open. 2020 09; 6(2).
    View in: PubMed
    Score: 0.173
  10. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020 01 08; 22(1):5.
    View in: PubMed
    Score: 0.165
  11. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019 07; 78(7):988-995.
    View in: PubMed
    Score: 0.157
  12. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. J Autoimmun. 1999 Mar; 12(2):137-42.
    View in: PubMed
    Score: 0.156
  13. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997 Nov; 9(6):527-35.
    View in: PubMed
    Score: 0.142
  14. Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients. Arthritis Care Res (Hoboken). 2017 07; 69(7):1088-1094.
    View in: PubMed
    Score: 0.139
  15. Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. Pediatr Rheumatol Online J. 2016 Nov 29; 14(1):64.
    View in: PubMed
    Score: 0.133
  16. Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis Rheumatol. 2016 Mar; 68(3):761-8.
    View in: PubMed
    Score: 0.127
  17. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine (Baltimore). 2014 Nov; 93(24):318-332.
    View in: PubMed
    Score: 0.115
  18. An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes: description and long-term follow-up of the anti-Nup syndrome. Medicine (Baltimore). 2014 Nov; 93(24):383-394.
    View in: PubMed
    Score: 0.115
  19. Analysis of the specificity of anti-PM-Scl autoantibodies. Arthritis Rheum. 1994 Oct; 37(10):1445-52.
    View in: PubMed
    Score: 0.115
  20. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2014 May; 66(5):732-40.
    View in: PubMed
    Score: 0.111
  21. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013 Jul; 92(4):223-243.
    View in: PubMed
    Score: 0.105
  22. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013 Jan; 92(1):25-41.
    View in: PubMed
    Score: 0.102
  23. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992 Jul; 35(7):821-30.
    View in: PubMed
    Score: 0.098
  24. Autoantibodies in polymyositis. Rheum Dis Clin North Am. 1992 May; 18(2):455-82.
    View in: PubMed
    Score: 0.097
  25. Polymyositis. Immunol Ser. 1991; 54:201-46.
    View in: PubMed
    Score: 0.088
  26. Immune mechanisms in myositis. Curr Opin Rheumatol. 1990 Dec; 2(6):882-8.
    View in: PubMed
    Score: 0.088
  27. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol. 2011 May 05; 148(3):261-70.
    View in: PubMed
    Score: 0.087
  28. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990 Sep; 33(9):1361-70.
    View in: PubMed
    Score: 0.086
  29. Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2010 Dec; 49(12):2381-90.
    View in: PubMed
    Score: 0.086
  30. Diagnosis and treatment of polymyositis and dermatomyositis. Compr Ther. 1990 Apr; 16(4):16-24.
    View in: PubMed
    Score: 0.084
  31. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990 Mar; 88(3):241-51.
    View in: PubMed
    Score: 0.083
  32. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol. 1990 Mar 01; 144(5):1737-43.
    View in: PubMed
    Score: 0.083
  33. Immunologic aspects of myositis. Curr Opin Rheumatol. 1989 Dec; 1(4):432-42.
    View in: PubMed
    Score: 0.082
  34. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest. 1989 Jul; 84(1):162-72.
    View in: PubMed
    Score: 0.080
  35. Humoral immunity in polymyositis and dermatomyositis. Mt Sinai J Med. 1988 Nov; 55(6):487-93.
    View in: PubMed
    Score: 0.076
  36. Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum. 1988 Apr; 31(4):515-24.
    View in: PubMed
    Score: 0.073
  37. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol. 1988 Apr-Jun; 6(2):76-92.
    View in: PubMed
    Score: 0.073
  38. Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum. 2007 Aug; 56(8):2719-28.
    View in: PubMed
    Score: 0.070
  39. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007; 9(4):R78.
    View in: PubMed
    Score: 0.067
  40. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 2006 Nov; 54(11):3670-81.
    View in: PubMed
    Score: 0.066
  41. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore). 2006 Mar; 85(2):111-127.
    View in: PubMed
    Score: 0.063
  42. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005 Jul; 84(4):231-249.
    View in: PubMed
    Score: 0.060
  43. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. Arthritis Rheum. 2004 Nov; 50(11):3646-50.
    View in: PubMed
    Score: 0.058
  44. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum. 2002 Jul; 46(7):1885-93.
    View in: PubMed
    Score: 0.049
  45. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther. 2020 04 06; 22(1):69.
    View in: PubMed
    Score: 0.042
  46. Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease. J Rheumatol. 2000 Jan; 27(1):161-4.
    View in: PubMed
    Score: 0.041
  47. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum. 1998 Apr; 41(4):710-9.
    View in: PubMed
    Score: 0.037
  48. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996 Sep; 39(9):1507-18.
    View in: PubMed
    Score: 0.033
  49. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome. Arthritis Rheum. 1996 Apr; 39(4):692-7.
    View in: PubMed
    Score: 0.032
  50. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med. 1995 May 01; 122(9):715-24.
    View in: PubMed
    Score: 0.030
  51. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. J Rheumatol. 1995 Apr; 22(4):762-5.
    View in: PubMed
    Score: 0.030
  52. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994 Oct; 37(10):1534-8.
    View in: PubMed
    Score: 0.029
  53. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993 Jun; 91(6):2556-64.
    View in: PubMed
    Score: 0.026
  54. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993 Apr; 94(4):379-87.
    View in: PubMed
    Score: 0.026
  55. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993 Jan; 100(1):116S-123S.
    View in: PubMed
    Score: 0.025
  56. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991 Nov; 70(6):360-74.
    View in: PubMed
    Score: 0.023
  57. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991 Nov; 34(11):1391-6.
    View in: PubMed
    Score: 0.023
  58. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum. 1990 Aug; 33(8):1240-8.
    View in: PubMed
    Score: 0.021
  59. C4 null genes in American whites and blacks with myositis. J Rheumatol. 1990 Mar; 17(3):331-4.
    View in: PubMed
    Score: 0.021
  60. Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity. J Immunol. 1987 May 01; 138(9):2874-82.
    View in: PubMed
    Score: 0.017
  61. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 1985 Jul; 28(7):796-803.
    View in: PubMed
    Score: 0.015
  62. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol. 1984 Jan; 4(1):40-4.
    View in: PubMed
    Score: 0.014
  63. Antibodies to Mi-1 in SLE: relationship to other precipitins and reaction with bovine immunoglobulin. Clin Exp Immunol. 1983 Jul; 53(1):76-82.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES